Dexamethasone solution and dexamethasone in Mucolox™ for the treatment of oral inflammatory ulcerative diseases: A phase II randomized clinical trial
Open Access
- 7 August 2023
- journal article
- research article
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 52 (9) , 860-866
Abstract
Background: Mucolox™ is a mucosal drug delivery system that prolongs the contact time between the oral mucosa and topical corticosteroids, potentially reducing the need for multiple applications daily. This study aimed to assess the clinical efficacy and tolerability of dexamethasone 0.5 mg/5 mL solution in Mucolox™ for the management of oral inflammatory ulcerative diseases.Methods: Participants were randomly assigned to receive dexamethasone 0.5 mg/5 mL in Mucolox™ (Mucolox™ arm) or dexamethasone 0.5 mg/5 mL solution (standard arm) and instructed to swish/gargle for 5 min three times daily. Changes from pre‐ to posttreatment patient's sensitivity score (0–10 on a visual analog scale), reticulation/erythema/ulceration score, and oral health‐related quality of life were evaluated at baseline and at the end of the study period.Results: Twenty nine patients (75% females) with a median age of 58 years (range 18–79) were enrolled and randomly allocated to the Mucolox™ or standard arm. One subject was excluded. Although statistically significant in both arms, the pre‐ to posttreatment sensitivity score reduction was higher in the Mucolox™ arm (6.3 vs. 4.4‐point reduction). Both arms showed a decrease in the reticulation/erythema/ulceration score between the two visits (7.2 vs. 4.7 [Mucolox™ arm]; 8.0 vs. 4.8 [standard arm]; p > 0.05). Mucolox™ in dexamethasone 0.5 mg/5 mL solution was better tolerated when taste and level of comfort were considered.Conclusions: Both treatments were effective in the management of oral inflammatory ulcerative diseases. Dexamethasone 0.5 mg/5 mL in Mucolox™ was better tolerated and was slightly better in controlling patients' oral sensitivity. Larger studies are needed to confirm these findings in oral inflammatory ulcerative diseases patients.Trial Registration: ClinicalTrials.gov Identifier: NCT04540133.Keywords
This publication has 13 references indexed in Scilit:
- Interventions for treating oral lichen planus: corticosteroid therapiesCochrane Database of Systematic Reviews, 2020
- Pemphigus: Current and Future Therapeutic StrategiesFrontiers in Immunology, 2019
- Comparison between self‐formulation and compounded‐formulation dexamethasone mouth rinse for oral lichen planus: a pilot, randomized, cross‐over trialJournal of Investigative and Clinical Dentistry, 2016
- Mucoadhesive vs. mucopenetrating particulate drug deliveryEuropean Journal of Pharmaceutics and Biopharmaceutics, 2016
- World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoidOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2015
- NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group ReportTransplantation and Cellular Therapy, 2015
- Oral Mucosal DiseasesMedical Clinics of North America, 2014
- Scoring system for monitoring oral lichenoid lesions: A preliminary studyOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2005
- Patient-centred outcome measures in oral medicine: are they valid and reliable?International Journal of Oral and Maxillofacial Surgery, 2002
- Oral lichen planusThe Journal of the American Dental Association, 2001